Lobe Sciences Ltd. will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. CFO Dr. David Kideckel will meet investors to discuss Lobe's lead drug candidate L-130, designed for cluster headaches and other neuropsychiatric disorders, and S-100 for sickle cell disease. The summit offers Lobe a platform to connect with Canadian and U.S. investors and advance its clinical-stage biotechnology programs. This event could boost investor interest and support for Lobe's novel therapies targeting neurological and rare diseases.
Douglas Thompson, Chief Operating Officer of CAVA, purchased 6,500 shares of the company valued at $432,000. This insider buying could signal confidence in CAVA's future prospects. Investors often view such purchases as a positive sign, potentially i...
Apple introduced the iPhone Duo, its first foldable smartphone, priced at a premium $2,000, significantly higher than previous flagship models. This launch aims to increase Apple's average selling price and margins, potentially enhancing earnings per...
Sonida Senior Living reported a strong Q2 performance following its $1.8 billion acquisition of CNL, with revenue rising 122% year-over-year. The integration of new communities has driven significant growth in net operating income (NOI) and improved ...
Colgate-Palmolive is reportedly looking to sell its Softsoap, Irish Spring, and Speed Stick brands as part of a strategic shift to concentrate on higher-growth oral and pet care sectors. The company has hired Goldman Sachs to manage the sale process,...
Microsoft has introduced a provisional code of conduct for its AI models, aiming to impose ethical limits and ensure AI serves people without replacing them. This move follows recent industry calls, including from Anthropic and OpenAI leaders, to slo...
